Aller au contenu principal
ProhibitedBinding ruleSAOriginal is EnglishImport de la source officielle contrôlé

Methylphenidate (INN) and its salts

Listed by the Saudi Food and Drug Authority as prohibited in cosmetic products.

Décision réglementaire et conditions complètes

Statut
Prohibited
Rôle juridique
Binding rule
Résumé réglementaire
Listed by the Saudi Food and Drug Authority as prohibited in cosmetic products.
Conditions et restrictions
A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Ouvrez la source citée et appliquez les exigences applicables à l’ensemble du marché ci-dessous.

Identité de la substance

Nom dans la source officielle
Methylphenidate (INN) and its salts
CAS
113-45-1
EC
Not supplied in this source row
Correspondance d’identité
standalone:official_sfda_record

Aperçu multi-marchés pour cette identité

Fiches exactes associées actuellement présentes sur ce site. L’absence d’un marché signifie qu’aucune correspondance exacte n’a été importée, et non une autorisation d’utiliser la substance.

10 jeux de données de marchés
Structure chimique 2D PubChem pour le CAS 113-45-1
CAS 113-45-1PubChem CID 4158

Chimie vérifiée pour le CAS 113-45-1

Methylphenidate

Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a methyl ester, a member of piperidines and a beta-amino acid ester. — ChEBI

Nom IUPAC
methyl 2-phenyl-2-piperidin-2-ylacetate
Formule moléculaire
C14H19NO2
Masse moléculaire
233.31 g/mol
Masse exacte
233.141578849 Da
Masse monoisotopique
233.141578849 Da
XLogP3
0,2
Surface polaire topologique
38,3 Ų
Complexité moléculaire
249,0
Charge formelle
0
Donneurs de liaisons hydrogène
1
Accepteurs de liaisons hydrogène
3
Liaisons rotatives
4
Atomes lourds
17
Unités covalentes
1

Noms et synonymes signalés à PubChem

MethylphenidanPhenidylateCalocainPlimasineMethyl phenidylacetateMetilfenidatoMethylphenidatumMethyl phenidate
16 autres noms signalés
4311/B CibaDaytranaalpha-Phenyl-2-piperidineacetic acid methyl esterMethyl alpha-phenyl-alpha-(2-piperidyl)acetateNCI-C56280Methyl 2-phenyl-2-(piperidin-2-yl)acetate2-Piperidineacetic acid, alpha-phenyl-, methyl esterCotempla XR-ODTMethyl alpha-phenyl-alpha-2-piperidinylacetatealpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl esterMetilfenidat hydrochlorideThreo-dl-methylphenidatePrc-063Methylphenidate extended releaseRitalineRefChem:6033
Identifiants de bases de données externes
Statistiques de structure avancées
Stéréocentres atomiques définis
0
Stéréocentres atomiques non définis
2
Stéréocentres de liaison définis
0
Stéréocentres de liaison non définis
0
Caractéristiques pharmacophoriques 3D
5
Cycles 3D
2
Groupes hydrophobes 3D
0
Caractéristiques d’accepteur 3D
1
Caractéristiques de donneur 3D
1
Centres anioniques 3D
0
Centres cationiques 3D
1
Conformères 3D
10
Rotors 3D effectifs
5,2
Identifiants de structure lisibles par machine
SMILES
COC(=O)C(C1CCCCN1)C2=CC=CC=C2
InChI
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
InChIKey
DUGOZIWVEXMGBE-UHFFFAOYSA-N

Preuves issues de bases de données scientifiques complémentaires

NIH PubChem PUG-View
Correspondance exacte d’identifiant4158

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. Source: Toxin and Toxin Target Database (T3DB)
  • Signal: Warning Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P264, P270, P271, P284, P301+P317, P304+P340, P330, P342+P316, P403, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Methylphenidate Hydrochloride is a psychostimulant used to treat different behavioral disorders. Indications: Used to treat narcolepsy and hyperkinetic states in children (as an adjunct to psychological, educational and social measures) for amphetamine, dextroamphetamine and ethylphenidate. It is misused for performance enhancement and relief of fatigue. Abuse either orally or by injection is extremely common. HUMAN EXPOSURE AND TOXICITY: Main risks include: Acute central nervous system (CNS) stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Cardiovascular effects include: palpitation, chest pain, tachycardia, arrhythmias and hypertension; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. CNS effects include: stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia. Stroke and cerebral vasculitis have been observed. Gastrointestinal effects include: vomiting, diarrhea and cramps. Genitourinary effects include: incre Source: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present. Source: StatPearls
  • Toxicity Summary: Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result. Source: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for methylphenidate(SRC), using a log Kow of 0.20(1) and a regression-derived equation(2). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to have low mobility in soil(SRC). The pKa of methylphenidate is 8.9(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species of methylphenidate from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Methylphenidate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.9(5) indicates methylphenidate will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.20(7) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Base-catalyzed second-order hydrolysis rate constant half-lives of 23 and 2.3 years at pH values of 7 and 8, respectively(2), suggest that hydrolysis may be a slow environmental fate process. Biodegradation data in water were not available(SRC, 2015). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), methylphenidate, which has an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase methylphenidate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 1 hr(SRC), calculated from its rate constant of 1.1X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase methylphenidate may be removed from the air by wet and dry deposition(SRC). Methylphenidate contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Methylphenidate (DEA Code Number: 1724) is a Schedule II controlled substance. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION (VET) Source: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Central Nervous System Stimulants; Dopamine Uptake Inhibitors Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >250; Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 9090; Consumption (g per capita) in Switzerland (2009): 0.032; Consumption (g per capita; approx.) in Germany (2009): 0.012; Consumption (g per capita) in the USA (2002): 0.032; Excretion rate: 0.1; Calculated removal (%): 92.1 Source: NORMAN Suspect List Exchange
  • Uses: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Source: Toxin and Toxin Target Database (T3DB)

Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source

Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.

Couverture des sources complémentaires et état des correspondances
SourceRésultatVérifié
NIH PubChem PUG-ViewCorrespondance exacte2026-08-31

Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.

Récupéré depuis NIH PubChem le 2026-09-02 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.

Source officielle et provenance

Source enregistrée
Saudi SFDA prohibited and restricted ingredient lists
Référence de la source
SFDA prohibited list, page 18, row 7
Identifiant de la fiche source
prohibited-17-7
Version de la source
live-snapshot-2026-08-30
Langue de la source
English
État de la traduction
Original is English
Instantané vérifié le
2026-08-30 05:18 UTC
Méthode de validation
complete SFDA paginated HTML snapshot; strict page/row counts
SHA-256
ceb6cc636e6b1f4b3013f88ce0297217b49d6194342c6ece5c03b1e04256d71a

Notes du jeu de données enregistré

Couverture du jeu de données
Prohibited and restricted substances with CAS, EC and conditions
Note sur l’autorité
Official SFDA dated lists; version and hash each release

Place de cette fiche dans le jeu de données du marché

2090
fiches Saudi Arabia actuelles
1726
fiches marquées Prohibited
2090
fiches de cette version de la source
1991
fiches du marché avec identité CAS

Répartition des statuts

Un texte de conditions est présent pour 0 des 2090 fiches actuelles. Un champ de conditions vide est interprété selon le type de fiche ci-dessus ; il n’est jamais converti en une affirmation d’utilisation sans restriction.

Saudi Arabia contexte du marché

Complete official list index

Version de la couverture : SFDA live prohibited/restricted lists, snapshot 30 August 2026

Every page and entry in the public SFDA prohibited and restricted ingredient indexes; restricted detail pages remain the source for conditions.

Liste de contrôle de vérification

  1. Search names and CAS across both SFDA lists.
  2. Open the cited restricted-entry detail and apply every condition.
  3. Check current SFDA/GSO technical regulations and updates.
  4. Complete eCosma notification, label and responsible-party requirements.

Sources officielles du marché

Procédure de vérification et exhaustivité de la fiche

Avant d’utiliser ce résultat dans une décision de conformité

  1. Confirmez que « Methylphenidate (INN) and its salts » et chaque identifiant CAS/CE correspondent à la matière de votre spécification fournisseur.
  2. Search names and CAS across both SFDA lists.
  3. Open the cited restricted-entry detail and apply every condition.
  4. Check current SFDA/GSO technical regulations and updates.
  5. Complete eCosma notification, label and responsible-party requirements.
  6. Consignez la version de la source et revérifiez auprès de l’autorité de réglementation avant la fabrication, la notification ou la mise sur le marché.

Champs disponibles dans cette fiche

  • Nom officiel de la substanceDisponible
  • CASDisponible
  • ECNon fourni
  • Texte de condition distinctAbsent de la ligne source
  • Date d’effetNon fourni
  • Empreinte de l’instantané et méthodeDisponible

Questions auxquelles cette page répond

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.

La fiche cite SFDA prohibited list, page 18, row 7, version de la source live-snapshot-2026-08-30. Ouvrir la source officielle.

Non. Le CAS aide à déterminer l’identité, mais les juridictions peuvent classer différemment une même substance et appliquer des champs d’application, limites, avertissements et dates de transition différents.

Citation stable

Methylphenidate (INN) and its salts. SFDA prohibited list, page 18, row 7. Saudi Arabia. Source version live-snapshot-2026-08-30. CosIng Checker regulatory record: https://cosingchecker.com/fr/regulations/sa/records/9776/

Citez l’autorité de réglementation comme autorité juridique. Cette page est un index structuré de preuves et une aide à la vérification, et non un substitut au texte officiel ni à une évaluation juridique professionnelle.

Interprétation et limites pour Saudi Arabia

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

Comment interpréter le rôle juridique

The cited row forms part of a binding rule or legally incorporated list for this market.

Preuves sur cette page

  • Résultat enregistré : Prohibited
  • Rôle juridique : Binding rule
  • Version de la source : live-snapshot-2026-08-30

Ce que cela ne prouve pas

No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.

Recherche complémentaire sur la substance auprès de sources faisant autorité

Aucune de ces sources ne prévaut sur la décision de marché ci-dessus.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Rechercher cette identité à la source

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Rechercher cette identité à la source

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Rechercher cette identité à la source

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Rechercher cette identité à la source

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Rechercher cette identité à la source

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Rechercher cette identité à la source

US EPA CompTox CTX APIs

Clé d’API requise pour l’import

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Rechercher cette identité à la source